207 related articles for article (PubMed ID: 19523016)
1. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education.
Selmer R; Sakshaug S; Skurtveit S; Furu K; Tverdal A
Br J Clin Pharmacol; 2009 Mar; 67(3):355-62. PubMed ID: 19523016
[TBL] [Abstract][Full Text] [Related]
2. Statin use in Canadians: trends, determinants and persistence.
Neutel CI; Morrison H; Campbell NR; de Groh M
Can J Public Health; 2007; 98(5):412-6. PubMed ID: 17985686
[TBL] [Abstract][Full Text] [Related]
3. The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes.
Andersson T; Nåtman J; Mourtzinis G; Bager JE; Bengtsson Boström K; Franzén S; Hjerpe P
Eur J Prev Cardiol; 2023 Nov; 30(17):1883-1894. PubMed ID: 37368941
[TBL] [Abstract][Full Text] [Related]
4. Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D: The case of statin utilization in the elderly with diabetes.
Lu ZK; Li M; Maxwell WD; Schulz RM
Res Social Adm Pharm; 2016; 12(3):419-27. PubMed ID: 26361822
[TBL] [Abstract][Full Text] [Related]
5. Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.
Wallach-Kildemoes H; Diderichsen F; Krasnik A; Lange T; Andersen M
BMC Public Health; 2012 Aug; 12():610. PubMed ID: 22863326
[TBL] [Abstract][Full Text] [Related]
6. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.
Marcus ME; Manne-Goehler J; Theilmann M; Farzadfar F; Moghaddam SS; Keykhaei M; Hajebi A; Tschida S; Lemp JM; Aryal KK; Dunn M; Houehanou C; Bahendeka S; Rohloff P; Atun R; Bärnighausen TW; Geldsetzer P; Ramirez-Zea M; Chopra V; Heisler M; Davies JI; Huffman MD; Vollmer S; Flood D
Lancet Glob Health; 2022 Mar; 10(3):e369-e379. PubMed ID: 35180420
[TBL] [Abstract][Full Text] [Related]
7. Time to improve statin prescription guidelines in low-risk patients?
Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
[TBL] [Abstract][Full Text] [Related]
8. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.
Robinson JG; Booth B
J Clin Lipidol; 2010; 4(6):483-90. PubMed ID: 21122695
[TBL] [Abstract][Full Text] [Related]
9. Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.
Byrne P; Cullinan J; Murphy C; Smith SM
BMJ Open; 2018 Feb; 8(2):e018524. PubMed ID: 29439070
[TBL] [Abstract][Full Text] [Related]
10. Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia.
Song SO; Kang MJ; Suh S
Medicine (Baltimore); 2024 Mar; 103(11):e37536. PubMed ID: 38489707
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.
Ko DT; Mamdani M; Alter DA
JAMA; 2004 Apr; 291(15):1864-70. PubMed ID: 15100205
[TBL] [Abstract][Full Text] [Related]
12. Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population.
Nilsson G; Samuelsson E; Söderström L; Mooe T
BMC Fam Pract; 2016 Aug; 17(1):110. PubMed ID: 27515746
[TBL] [Abstract][Full Text] [Related]
13. Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study.
Kiage JN; Sampson UK; Lipworth L; Fazio S; Mensah GA; Yu Q; Munro H; Akwo EA; Dai Q; Blot WJ; Kabagambe EK
Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):1016-24. PubMed ID: 26298428
[TBL] [Abstract][Full Text] [Related]
14. Family history of cardiovascular disease and influence on statin therapy persistence.
Citarella A; Kieler H; Sundström A; Linder M; Wettermark B; Berglind IA; Andersen M
Eur J Clin Pharmacol; 2014 Jun; 70(6):701-7. PubMed ID: 24604354
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and factors associated with statin use in high-risk patients with type 1 diabetes from a specialized diabetes unit.
Amor AJ; Ortega E; Giménez M; Cofán M; Blanco J; Pané A; Boswell L; Vinagre I; Esmatjes E; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019 Oct; 66(8):512-519. PubMed ID: 31000451
[TBL] [Abstract][Full Text] [Related]
16. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.
Ferket BS; van Kempen BJ; Heeringa J; Spronk S; Fleischmann KE; Nijhuis RL; Hofman A; Steyerberg EW; Hunink MG
PLoS Med; 2012; 9(12):e1001361. PubMed ID: 23300388
[TBL] [Abstract][Full Text] [Related]
17. Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New Zealand? Two cohort studies.
Rabanal KS; Meyer HE; Tell GS; Igland J; Pylypchuk R; Mehta S; Kumar B; Jenum AK; Selmer RM; Jackson R
BMJ Open; 2017 Dec; 7(12):e016819. PubMed ID: 29217719
[TBL] [Abstract][Full Text] [Related]
18. Statin prescribing for primary prevention of cardiovascular disease: a cross-sectional, observational study.
Homer K; Boomla K; Hull S; Dostal I; Mathur R; Robson J
Br J Gen Pract; 2015 Aug; 65(637):e538-44. PubMed ID: 26212850
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
20. [Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011].
Knopf HC; Busch MA; Du Y; Truthmann J; Schienkiewitz A; Scheidt-Nave C
Z Evid Fortbild Qual Gesundhwes; 2017 May; 122():22-31. PubMed ID: 28511896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
